Zealand Pharma A/S (OTCMKTS:ZLDPF) Stock Rating Upgraded by William Blair

William Blair upgraded shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) to a hold rating in a report released on Thursday,Zacks.com reports.

Other analysts have also issued reports about the company. JPMorgan Chase & Co. initiated coverage on Zealand Pharma A/S in a report on Friday, November 8th. They issued an “overweight” rating on the stock. Cantor Fitzgerald upgraded Zealand Pharma A/S to a “strong-buy” rating in a research note on Tuesday, January 21st.

Zealand Pharma A/S Stock Down 0.7 %

OTCMKTS:ZLDPF opened at $97.78 on Thursday. Zealand Pharma A/S has a 1 year low of $80.86 and a 1 year high of $141.74. The stock has a 50-day moving average price of $101.00 and a two-hundred day moving average price of $112.64. The stock has a market cap of $6.94 billion, a price-to-earnings ratio of -41.43 and a beta of 0.88. The company has a current ratio of 35.49, a quick ratio of 35.49 and a debt-to-equity ratio of 0.03.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last issued its quarterly earnings data on Thursday, February 20th. The company reported ($0.59) EPS for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.19. The business had revenue of $1.30 million for the quarter, compared to analyst estimates of $28.11 million. Zealand Pharma A/S had a negative net margin of 1,725.03% and a negative return on equity of 15.24%. As a group, equities analysts expect that Zealand Pharma A/S will post -2.19 earnings per share for the current year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.